Gefitinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="Erlotinib/Erlotinib/1" align="right" caption="Erlotinib, also known as Tarceva"/> ===Better Known as: Iressa=== * Mark... |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene =" | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Gefitinib/Gefitinib/1" align="right" caption="Gefitinib, also known as Iressa"/> | ||
===Better Known as: Iressa=== | ===Better Known as: Iressa=== | ||
* Marketed By: AstraZeneca & Teva | * Marketed By: AstraZeneca & Teva | ||
* Major Indication: Pancreatic & Small Cel Lung [[Cancer]] | * Major Indication: Pancreatic & Small Cel Lung [[Cancer]] | ||
* Drug Class: EGFR Inhibitor | * Drug Class: [[EGFR]] Inhibitor | ||
* Date of FDA Approval (Expiration): 2003 (2013) | * Date of FDA Approval (Expiration): 2003 (2013) | ||
* 2009 Sales: $268 Million | * 2009 Sales: $268 Million | ||
| Line 12: | Line 12: | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
! colspan="6" align="center"| | ! colspan="6" align="center"| [[Epidermal Growth Factor Receptor]] Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID:16609030</ref><ref>PMID:17482782</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
